HPV Infection in the Pathogenesis and Prognosis of HNSCC
========================================================

Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent and lethal cancers worldwide (Argiris et al., [@B5]). Despite recent advances in early detection, surgical techniques, radiation and chemotherapeutic regimes (Temam et al., [@B101]; Sheu et al., [@B92]), the survival rate and quality of life for patients with HNSCC has only marginally improved over the past few decades (Haddad and Shin, [@B34]; Masuda et al., [@B65]). There is a desperate need for better biomarkers, to identify patients at high-risk for treatment failure, as well as novel concepts for a more effective and less toxic therapy for patients with advanced tumors (Hunter et al., [@B44]; Leemans et al., [@B53]).

Head and neck squamous cell carcinoma has a strong epidemiologic background (Rodriguez et al., [@B88]; D'Souza et al., [@B21]; Furniss et al., [@B26]) including environmental and lifestyle factors. The major risk factors for HNSCC are tobacco and alcohol abuse; however, the escalating incidence of oropharyngeal carcinoma (oropharyngeal squamous cell carcinoma, OPSCC) are not explained by increases in either smoking and alcohol consumption suggesting that atypical behavioral and environmental factors are also involved (Ernster et al., [@B23]). Importantly, a subgroup of OPSCCs has causally been linked to infection with high-risk types of human papillomavirus (HPV), especially HPV16 (Gillison et al., [@B29]; Pai and Westra, [@B74]). HPV infection has been established as a causative agent for almost 70% of OPSCCs and 20--25% of all HNSCCs (Gillison et al., [@B30]; Begum et al., [@B9]; Kreimer et al., [@B51]; Reimers et al., [@B84]; Hoffmann et al., [@B41]). In recent years, HPV-related tumors have been shown to be a new tumor entity in itself, with distinct clinical and histopathological features, including younger median age, oropharyngeal primary anatomical site, small tumor size, high lymph node involvement, as well as a lack of typical risk factors, and increasing incidence over the last decades at variance with decreasing total HNSCC incidence. Furthermore, HPV-related tumors do not show significant keratinization and they have a prominent basaloid morphology. The differences between HPV-related and HPV-negative tumors have been reviewed in several excellent recent reviews (Argiris et al., [@B5]; Psyrri and Dimaio, [@B79]; Leemans et al., [@B53]).

Intriguingly, patients with a HPV-positive tumor have improved performance status and a better prognosis compared to HPV-negative patients, even though the former patients were more likely to present with regional lymph node metastasis at the time of diagnosis (Curado and Hashibe, [@B16]; Pai and Westra, [@B74]). In general, HPV-positive patients are highly curable with ionizing radiation with or without chemotherapy, and have better overall and disease-free survival compared to patients diagnosed with HPV-negative tumors (Figure [1](#F1){ref-type="fig"}) (Fakhry et al., [@B24]; Ang et al., [@B4]). However, in several studies HPV DNA-positive OPSCCs were heterogeneous in both biological and clinical behavior, possibly due to differences in viral load and/or viral oncogene expression (Paz et al., [@B76]; Andl et al., [@B3]; Klussmann et al., [@B50]; van Houten et al., [@B104]; Mellin et al., [@B66]; Wiest et al., [@B112]; Braakhuis et al., [@B11]; Lindquist et al., [@B55]; Reimers et al., [@B84]; Attner et al., [@B6]; Jung et al., [@B46]).

![**Classification of HNSCC according to HPV tumor status**. HPV-related tumors are distinct from non-HPV-related tumors in biological and clinical features, including response to radio- and chemotherapy and clinical outcome.](fonc-02-00036-g001){#F1}

Alterations in the Genome, Epigenome, and Transcriptome of HPV-Related Tumors
=============================================================================

Functional genome and transcriptome studies strongly suggest that HPV-related HNSCCs comprise a disease entity that differs from HPV-negative tumors in regard to distinct molecular characteristics. In the past, several groups used comparative genomic hybridization (CGH) to identify genomic imbalance in the pathogenesis of HNSCCs, focusing on HPV-related and HPV-negative tumors (Dahlgren et al., [@B17]; Smeets et al., [@B96]; Klussmann et al., [@B49]; Wilting et al., [@B114]). Despite tumor-associated genomic alterations, which are common in both groups, these studies highlighted that per tumor, the total amount of chromosomal alterations, as well as amplifications was significantly lower in the HPV-related than in the HPV-unrelated tumors (Table [1](#T1){ref-type="table"}). This finding is consistent with the assumption that due to the inactivation of the tumor suppressor proteins p53 and pRb by the viral E6 and E7 oncoproteins, respectively, the number of required genetic alterations for a malignant phenotype is lower in HPV-related carcinogenesis. Consequently, a better clinical outcome of patients with HPV-related tumors could simply be a reflection of less genetic aberrations at the time of treatment. However, specific HPV-related genetic alterations have also been identified (Table [1](#T1){ref-type="table"}) some of which were connected with improved survival. For example, 16q loss, which was predominantly identified in HPV-related OPSCC, was a strong indicator of favorable outcome and none of these patients had a tumor recurrence (Klussmann et al., [@B49]). Additionally, HPV-negative tumors demonstrate a loss at 18q12.1--23, in contrast to a gain in HPV-positive tumors (Smeets et al., [@B96]). It will be a major challenge in the future to identify candidate genes at the affected genomic sites, and to investigate their contribution to treatment resistance and tumor cell survival in both patient cohorts as well as preclinical model systems.

###### 

**Alteration in the genome of HNSCCs: genomic aberrations characteristic for HPV-related OPSCC**.

  HPV-dependent genomic aberration                                         Reference
  ------------------------------------------------------------------------ ---------------------------
  3p25, 9p21, 11q13, and 16q12--24                                         Jung et al. ([@B46])
  3p, 5q, 8p, 11q, 13q, and 20q                                            Wilting et al. ([@B114])
  3p, 5q, 9p, 11q13, 15q, 16q, 18q, and Xp                                 Klussmann et al. ([@B49])
  3p11.2--26.3, 5q11.2--35.2, 9p21.1--24, 11q12.1--13.4, and 18q12.1--23   Smeets et al. ([@B96])
  3q24--qter and 7q11.2--q22                                               Dahlgren et al. ([@B17])

To uncover the genetic origin and the mutational landscape of HNSCC, two recent studies applied gene copy number and whole exome sequence analysis on specimens of tumor--normal pairs, including samples from patients with HPV-related tumors (Agrawal et al., [@B1]; Stransky et al., [@B99]). In both studies, the majority of tumors exhibited a mutational profile consistent with tobacco exposure, and there were obvious differences in the genetic landscapes of HPV-related and HPV-negative HNSCCs. For instance, tumors that were negative for HPV had more mutations than HPV-positive tumors, independently of the smoking status. This finding is in line with the data derived by CGH analysis and further confirms major differences in the pathogenesis of HPV-related and HPV-negative tumors. Furthermore, both studies observed an inverse correlation between the HPV status and *TP53* mutations, as already shown previously (Wiest et al., [@B112]; Westra et al., [@B111]).

In addition to genomic alteration and gene mutation, aberrant DNA methylation is widely recognized as a mechanism in the progression of HNSCC (Hasegawa et al., [@B38]; Schmezer and Plass, [@B91]), but our knowledge on virus-induced changes in DNA methylation of the host genome as well as other modes of epigenetic alterations, as part of the divergent carcinogenic pathway, is limited. Nevertheless, the identification of distinct epigenetic profiles in HPV-related and HPV-negative tumors should provide clues to novel drug targets for development of individualized therapeutic strategies. Currently, there is a limited number of studies which address the differences in epigenetic alteration between HPV-related and HPV-negative tumors. Furthermore, the published data has largely evaluated changes in promoter methylation of a limited number of candidate genes, most of which were selected based on functional relevance in several human malignancies (Table [2](#T2){ref-type="table"}). A more recent study by Sartor et al. ([@B89]) applied an integrative approach combining genome-wide methylation and gene expression profiling to characterize the molecular differences between HPV-related and HPV-negative tumor cell lines. They found a higher overall DNA methylation in HPV-positive compared to HPV-negative cell lines. This HPV-dependent difference was consistent with findings in primary tumor samples and in line with data from Richards et al. ([@B85]). Moreover, an inverse correlation between gene promoter methylation and expression of affected genes was found in HPV-positive cells (Sartor et al., [@B89]). Although differentially methylated loci found in tumor cell lines were significantly correlated with primary tumor DNA methylation levels, a recent study demonstrated major changes in the DNA methylation pattern between cultured cells and primary tumors (Hennessey et al., [@B40]). Although these findings may direct alterations in the epigenome to different disease pathways involved in HPV-related versus HPV-negative tumors, critical validation in larger HNSCC tumor sample sets is required.

###### 

**Summary of genes affected by DNA methylation in HNSCC**.

  Study                           Genes/proteins                                                                                                                                 T     CL   HPV
  ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ----- ---- -----
  El-Naggar et al. ([@B22])       CDKN2A                                                                                                                                         46    11   −
  Hasegawa et al. ([@B38])        CDKN2A, DAPK, ECAD, RASSF1A                                                                                                                    80    −    
  Dong et al. ([@B20])            RASSF1A                                                                                                                                        46    7    \+
  Wong et al. ([@B115])           CDKN2B, CDKN2A                                                                                                                                 73    −    −
  Puri et al. ([@B80])            MLH1, MGMT, CDKN2A                                                                                                                             51    −    −
  Marsit et al. ([@B60])          SFRP family                                                                                                                                    350        \+
  Weber et al. ([@B109])          SOCS-1, SOCS-3                                                                                                                                 94    −    −
  Dikshit et al. ([@B19])         MGMT, DAPK, E-cadherin                                                                                                                         235   −    −
  Kim et al. ([@B48])             CDKN2A, BIRC5, HIF1A, SKP1, CCNA, CCNB, c-myc, EGFR                                                                                            52    −    \+
  Martone et al. ([@B63])         MGMT, CDKN2A, DAPK                                                                                                                             20    −    −
  Righini et al. ([@B86])         TIMP3, ECAD, FHIT, APC, DCC, hMLH1, THSB1, RARβ S100A9, CDKN2B, CDKN2A, MGMT, DAPK, ATM, CASP8, RASSF1                                         90    −    −
  Carvalho et al. ([@B14])        DCC, DAPK, TIMP3, ESR, CCNA1, CCND2, MINT1, MINT31, CDH1, AIM1, MGMT, CDKN2A, PGP9.5, RARB, HIC1, RASSF1A, CALCA, TGFBR2, S100A2, RIZ1, RBM6   211   −    −
  Marsit et al. ([@B61])          ECAD                                                                                                                                           340   −    \+
  Taioli et al. ([@B100])         MGMT, CDKN2A, RASSF1A                                                                                                                          88    −    \+
  Marsit et al. ([@B59])          773 genes                                                                                                                                      68    −    −
  Munoz-Antonia et al. ([@B68])   TbetaR-I                                                                                                                                       50    −    −
  Weiss et al. ([@B110])          TIMP3, CDH1, CDKN2A, DAPK1, TCF21, CD44, MLH1, MGMT, RASSF1A, CCNA1, LARS2, CEBPA                                                              55    −    \+
  Sartor et al. ([@B89])          DNMT3A, CCNA1, CDKN2A, KRT8, RUNX2, IRS, PcG genes                                                                                             −     4    \+
  Gubanova et al. ([@B32])        SMG-1                                                                                                                                          34    2    \+

*Genes/proteins, specific gene(s) or protein(s; or total number) of genes investigated in each study; T, total number of tumors/patients included in the study; CL, number of different cell lines included in the study; HPV, consideration of HPV status in the study*.

Global gene expression profiling comparing HPV-related and HPV-negative tumors revealed distinct transcriptome signatures, reflecting underlying heterogeneous somatic, genetic, and epigenetic alterations. As it would have been expected, all published studies identified differentially expressed genes that regulate DNA replication and cell cycle progression (Slebos et al., [@B95]; Martinez et al., [@B62]; Pyeon et al., [@B81]; Lohavanichbutr et al., [@B56]), while some also describe aberrant regulation of genes involved in viral defense and immune response (Schlecht et al., [@B90]; Jung et al., [@B46]). It is worth to mention that some differentially expressed genes are already known to modulate resistance to radiation and chemotherapeutic drugs, but experimental evidence of their impact on the favorable outcome of patients with HPV-related tumors are still missing. Moreover, dysregulation of genes associated with processes of Natural Killer Cell-mediated cytotoxicity, activation of the Toll-like receptor, JAK--STAT signaling pathways (Jung et al., [@B46]), as well as immune response and inflammation (Schlecht et al., [@B90]), are of particular interest, assumpting that the mechanisms underlying the clinical differences of HPV-related and HPV-negative tumors may involve the combined effects of immune surveillance to viral-specific tumor antigens, an intact apoptotic response to radiation, and the absence of widespread genetic alterations (Pai and Westra, [@B74]). Yet, the correlation between altered cytokine and interferon signaling and the HPV status further supports the conclusion that improved survival of patients with HPV-related tumors may not only depend on tumor cell intrinsic features, but also could be due to different activation of stromal cells within the tumor microenvironment (Figure [2](#F2){ref-type="fig"}).

![**Intrinsic and extrinsic features of HPV-related HNSCC tumors potentially involved in the molecular mechanisms underlying improved disease course**. HPV-related tumors have a better survival likely due to the combined effects of phenomena occurring in epigenome, genome, and transcriptome. These events drive alternations in intracellular signaling networks and along with complex interactions of malignant cells with components of tumor microenvironment including immune cells, they orchestrate the improved response to treatment and the favorable outcome.](fonc-02-00036-g002){#F2}

MicroRNAs (miRNAs) are small non-coding RNAs, which represent another mode of gene regulation by influencing mRNA translation or decay. Several studies reported altered expression of distinct miRNAs in the pathogenesis of HNSCC (Babu et al., [@B7]). Two recent studies characterized the influence of HPV on global miRNA expression in HNSCC cell lines (Wald et al., [@B106]), and tumor biopsies of HNSCC patients (Lajer et al., [@B52]), respectively. Although, the overlap on common deregulated miRNAs is only minor (which may be due to the use of cell lines versus tumor biopsies) increasing our understanding of the virus-targeted miRNAs may provide further insight into molecular mechanisms for the distinct clinical behavior of HPV-related tumors.

Cell Intrinsic Features of HPV-Positive Tumor Cells
===================================================

Several intrinsic hallmarks of tumor cells have been described, including: (i) sustaining proliferative signaling, (ii) evading growth suppressors, (iii) resisting apoptosis, (iv) enabling unlimited replication, (v) inducing angiogenesis, and (vi) activating invasion and metastasis (Hanahan and Weinberg, [@B36], [@B37]). However, which of these capabilities differ between HPV-related and HPV-positive tumor cells and their likely contribution to the differential clinical outcome, is still a matter of debate. For instance, while patients with HPV-related HNSCC respond better to radiotherapy, there is controversial data concerning whether HPV-related tumor cells are indeed inherently more radiosensitive than HPV-negative cells (Pai and Westra, [@B74]).

Infection by HPV results in over-expression of the viral oncoproteins and thereby affects many cellular pathways as well as genome stability. The oncogenic potential of HPV involves the expression of the viral E6 and E7 oncoproteins, which disrupts the tumor suppressive p53 and pRB signaling pathways, respectively, and thereby modulate cell cycle progression and survival of infected keratinocytes (Zur Hausen, [@B118]). Continued expression of viral oncogenes is necessary for neoplastic progression and the malignant phenotype of an HPV-associated tumor. Transcriptionally active viral DNA has been shown to be biologically and clinically relevant (Figure [1](#F1){ref-type="fig"}) (Wiest et al., [@B112]; Fakhry et al., [@B24]; Jung et al., [@B46]). HPV-related HNSCCs have less frequent p53 or pRB mutations, which often occur in HPV-negative tumors (Marur et al., [@B64]). The tumor suppressor p53 acts as a central mediator of the cellular stress response, including DNA damage induced apoptosis and cellular senescence by chemotherapy and ionizing radiation. Therefore, the presence of wild-type p53 in HPV-related tumors could, at least in part, confer accelerated chemo- and radiosensitivity compared to HPV-negative tumors with p53 mutations. Licitra et al. ([@B54]) found that the clinical behavior of HNSCC patients critically depends on the HPV and the p53 status. They provided clinical evidence that only patients with HPV-related tumors and wild-type p53 exhibit an improved survival, while patients with HPV-related tumors and mutant p53 have an unfavorable outcome, similar to HPV-negative HNSCC patients. However, in a more recent publication Pang et al. ([@B75]) showed that expression of the viral E6 oncogene sensitizes tumor cells to radiation-induced apoptosis, and that the E6^\*^I, and not the E6^\*^II isoform, is sufficient to mediate this effect. Interestingly, E6^\*^I was shown to be a weak inhibitor of p53 transactivator activity, and the study supports a role for E6^\*^I in the enhanced responsiveness of HPV-positive OPSCCs to p53-independent radiation-induced cell death.

The finding that nuclear Survivin is associated with HPV-negative compared to HPV-related OPSCC and correlated with a poor clinical outcome further suggests a fundamental role in cell death regulation (Preuss et al., [@B77]). Survivin is an inhibitor of apoptosis (IAP) and nuclear Survivin is believed to control cell division, whereas cytoplasmic Survivin is considered cytoprotective (Stauber et al., [@B98]). HNSCC cases with nuclear Survivin and Aurora-B expression exhibited marked malignant behaviors whereas both Survivin and Aurora-B knockdown inhibited cell growth and tumor formation (Qi et al., [@B82]). Furthermore, Survivin also plays a critical role in mediating resistance to radiation in part through suppression of apoptosis.

More recently, Gubanova et al. investigated whether the mechanism underlying increased sensitivity of HPV-positive tumors to radiation may be connected to the impaired ability of the cancer cells to respond to DNA damage. They found that expression of SMG-1 (suppressor with morphogenetic effect on genitalia) is diminished in HPV-positive tumors due to gene promoter hypermethylation (Gubanova et al., [@B32]). SMG-1 belongs to a family of phosphoinositide 3-kinase (PI3-kinase)-related kinases (PIKKs) involved in the maintenance of genome integrity via genotoxic stress response pathways and plays an important role in the DNA damage response network (Shiloh, [@B93]; Brumbaugh et al., [@B13]; Gewandter et al., [@B28]). Low SMG expression correlated with positive HPV status and improved patient survival, whereas depletion of SMG-1 in HNSCC cells resulted in their increased sensitivity to radiation (Gubanova et al., [@B32]).

The impact of HPV E6 and E7 oncoproteins in *in vitro* cell sensitization to radiation remains controversial, since other studies have suggested that HPV16-positive cervical cancer cells (Padilla et al., [@B72]) and HNSCC cells (Hoffmann et al., [@B43]) as well as HPV-negative cells with ectopic E6 and E7 expression (Hampson et al., [@B35]) are resistant to treatment with cytotoxic drugs and radiation. It is worth noting that increased expression of another IAP molecule, namely CIAP2, was reported to be significantly associated with HPV16-related HNSCCs (Mansour et al., [@B58]). Viral E6 oncoprotein has been shown to induce CIAP2 expression through either the NF-κB or EGFR/PI3K/AKT signaling pathways. CIAP2 confers less sensitivity to apoptosis in HPV16 E6-immortalized human oral keratinocytes (Yuan et al., [@B117]; James et al., [@B45]), and resistance to cisplatin in HPV-infected lung cancer (Wu et al., [@B116]), or 5-FU treatment of HNSCC cell lines (Nagata et al., [@B70]). Furthermore, high CIAP2 expression was associated with poor clinical outcome, at least in patients with oral squamous cell carcinoma (Nagata et al., [@B70]).

Impact of the Immune System
===========================

Although there is a growing body of *in vivo* and *in vitro* data supporting the assumption that HPV-related tumors have a better survival due to a higher sensitivity to radiation and chemotherapy, it is difficult to conclusively attribute the improved clinical outcome only to the intrinsic features of the HPV-infected cells. It is more likely that a complex paracrine interaction among intrinsically mediated key pathways and the tumor microenvironment, including cells of the immune system, may determine the accelerated sensitivity to either radiation or chemotherapy (Figure [2](#F2){ref-type="fig"}). Accordingly, HPV-positive tumors have been postulated to be more susceptible to immune surveillance of tumor-specific antigens (Argiris et al., [@B5]), but so far only a few studies have explored endogenous host immunity to viral proteins in HNSCC patients, in order to elucidate pathogenetic and treatment--response mechanisms, and to gain insights into novel immunotherapeutic strategies.

Cytotoxic therapies including radiation induce potentially immunogenic cell death, releasing tumor-associated antigens, as a "danger" signal to the immune system (Shinohara and Maity, [@B94]). The efficacy of radiotherapy is determined not only by tumor cell properties, but also endothelial cells and infiltrating immune cells within the tumor environment (Shinohara and Maity, [@B94]). High levels of tumor-infiltrating lymphocytes (TILs) have been identified as a favorable prognostic biomarker in various cancers (Pages et al., [@B73]), including HNSCC (Brandwein-Gensler et al., [@B12]; Lopez-Albaitero et al., [@B57]; Uppaluri et al., [@B103]). However, their exact role on HNSCC, especially in the context of HPV-related tumors remains to be elucidated. In this context, Hoffmann et al. found that the frequency of HPV16-E7-specific T cells in the serum did not differ between HNSCC patients and healthy controls. However, higher frequencies of T cells specific for HPV16-E7 epitopes were observed in HNSCC patients with HPV-related tumors (Hoffmann et al., [@B42]), which is in line with previous findings (Albers et al., [@B2]). The fact that HPV16-E7 epitopes are apparently immunogenic raises the question as to why antigen-specific T cells in HNSCC patients are unable to eliminate HPV-related tumors without treatment. One possible explanation was provided by the finding that E7-specific cytotoxic T cells obtained by *in vitro* stimulation only recognize human leukocyte antigen HLA-A^\*^201 positive and HPV16-transformed HNSCC cells after pretreatment with IFN-gamma (Albers et al., [@B2]). Further analysis demonstrated that this cell line had little or no expression of critical components of the HLA class I antigen-processing machinery, which were subsequently up-regulated upon IFN-gamma treatment. In addition, the antigen-processing machinery components were also found to be downregulated in HPV-related tumors compared to adjacent normal epithelium. It currently remains uncertain as to whether impaired antigen presentation in HPV-related tumors may be reversed by radiation or chemotherapy and thereby induces an antitumor immune response.

In a retrospective study, Rajjoub et al. ([@B83]) reported a positive correlation between large numbers of TILs (CD3^high^) and lower incidence of metastasis at presentation, regardless of HPV status. However, when the HPV status was taken into account, the correlation between a CD3^high^ count and a lower rate of metastasis was maintained in HPV-positive but not in HPV-negative patients (Rajjoub et al., [@B83]), further supporting the crucial role of the adaptive immunity in the favorable clinical outcome of HPV-related tumors. In line with this assumption, the percentage of circulating CD8-positive T cells was significantly higher in patients with HPV-related tumors as compared to HPV-negative HNSCC patients (Wansom et al., [@B108]). Furthermore this prospective study revealed a positive correlation between a higher percentage of CD8-positive T cells and the response to induction chemotherapy and complete tumor response after chemotherapy. However in a subsequent study, Wansom et al. ([@B107]) reported that the degree of T cell infiltration in tumor tissue is associated with improved survival but is independent of the HPV status, similar to previous findings (Rajjoub et al., [@B83]; Wansom et al., [@B107]). They concluded that more comprehensive studies with larger numbers of patients combined with functional analysis of individual subsets may be necessary to detect significant differences in local immunity in HPV-related HNSCC.

There is increasing evidence that radiotherapy modulates immune response and that the underlying mechanism behind the better prognosis of HPV-positive tumors may be enhanced immune response following radiotherapy (Vu et al., [@B105]). In a recent study, Spanos et al. ([@B97]) found that both HPV-positive human and murine transformed cell lines cells were even more resistant to radiation and cisplatin treatment *in vitro* compared with HPV-negative counterparts. However, HPV-positive cells were more sensitive to radiation in a syngeneic mouse tumor model, and complete clearance was found at 20 Gy, in contrast to HPV-negative cells, which showed persistent growth (Spanos et al., [@B97]). Similar data were also obtained upon cisplatin treatment. Intriguingly, neither radiation nor cisplatin therapy cured HPV-positive tumors in immune-incompetent mice, strongly supporting a crucial role of the immune system in the therapeutic sensitivity of HPV-positive tumors. In line with this assumption, Williams et al. ([@B113]) showed in a syngeneic mouse tumor model that only HPV-positive tumor cells induce an antigen-specific antitumor response, which was mediated by CD4- and CD8-positive T lymphocytes.

Innate immune cells may also contribute to the favorable clinical outcome of patients with HPV-related OPSCCs. As basal keratinocytes are the primary target of HPV infection (Feller et al., [@B25]), innate immunity represents the first line of defense against invading viruses. Keratinocytes express several pathogen recognition receptors (PRRs; Pries et al., [@B78]), and their engagement by pathogen-associated or danger-associated molecular patterns leads to direct activation of the pro-inflammatory transcription factors, and/or activation of an anti-viral type I interferon (IFN) response (Rincon-Orozco et al., [@B87]; Muto et al., [@B69]). Several reports highlighted a major impact of viral oncoproteins on the regulation of pro-inflammatory mediators and anti-viral responses, suggesting that HPV has developed strategies to evade the innate host immunity (Schlecht et al., [@B90]; Jung et al., [@B46]; Karim et al., [@B47]). For example, expression of the pro-inflammatory molecules S100A8 and S100A9 were downregulated in HPV-immortalized cells (Dell'oste et al., [@B18]). Vice versa, the S100A8/S100A9 protein complex has been shown to inhibit phosphorylation of the viral E7 oncoprotein by the casein kinase II and may play an important role in HPV-infected epithelial cells to counteract the oncogenic activity of E7 (Tugizov et al., [@B102]). S100A8 (MRP8) and S100A9 (MRP14) belong to the large family of S100 proteins, which are low molecular weight proteins sharing conserved structural motifs that consist of two EF-hand Ca^2+^-binding domains. S100A8 and S100A9 form a functional heterodimer (also known as calprotectin) and have been identified as important endogenous damage-associated molecular pattern proteins that critically contribute to pathological conditions of acute and chronic inflammation, and may therefore represent a key player in the setting of inflammation-associated carcinogenesis (Gebhardt et al., [@B27]; Nemeth et al., [@B71]). It is worth mentioning, that inflammatory signals and the establishment of a pro-inflammatory environment are increasingly linked to the induction and promotion of tumorigenesis (Balkwill and Mantovani, [@B8]; Coussens and Werb, [@B15]; Grivennikov et al., [@B31]). One of the most extensively studied signaling network in inflammation-associated cancer is the NF-κB pathway (Ben-Neriah and Karin, [@B10]), and there is increasing evidence for its crucial role in the pathogenesis of HNSCC including HPV-related tumors (Molinolo et al., [@B67]). Analysis of HPV16-transformed cell lines revealed that functional components of the NF-κB signaling pathway were sequestered in the cytoplasm, or became inactivated by viral E6 and E7 expression, accompanied by reduced expression of cytokines and chemokines (Guess and McCance, [@B33]; Havard et al., [@B39]). However, it will be a challenge for the future to address the question of whether changes in pro-inflammatory signaling pathways, such as NF-κB, and the establishment of an activated pro-tumorigenic environment are causally linked to the increased sensitivity to therapy of patients with HPV-related tumors and their improved survival.

Conclusion and Perspectives
===========================

Currently, HPV-positive OPSCC dominates the head and neck oncology landscape, and its escalating incidence has a strong impact on clinical and translational research. Although it is well accepted that HPV-related tumors represent a distinct histopathological and biological entity with a favorable clinical outcome, we have just now begun to establish the molecular principles underlying improved survival. As a consequence of modern genome-wide approaches, our understanding of the fundamental mechanisms and biological processes involved in the pathogenesis of HPV-related and HPV-negative HNSCCs has rapidly increased. However, most of the functional genomics data was derived from primary tumor samples largely devoid of the important information on differences in response to current treatment options. Furthermore, the use of several cell culture and mouse tumor models have produced conflicting results which neither mimic the complex interaction between the tumor and its activated tumor microenvironment nor the etiology of HPV-related tumors. Hence, there is an urgent need for an appropriate and more sophisticated preclinical model system(s).

The mechanisms underlying the clinical differences between HPV-related and HPV-negative tumors may involve the combined effects of tumor cell intrinsic features and paracrine interactions between tumor cells and stromal cells of the activated tumor microenvironment, especially cells of the adaptive and innate immunity. Unraveling the molecular nature of improved clinical outcome of HPV-related HNSCC will not only support personalized risk assessment but will also unravel new concepts for a targeted therapy for HNSCC patients with HPV-negative tumors.
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